You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The assay, called the single telomere absolute-length rapid (STAR) assay, uses Fluidigm microfluidic chips and was found to be accurate and sensitive.
JPM moved to an Overweight rating on both companies from a Not Rated designation assigned during a restriction period as Thermo Fisher's potential acquisition of Qiagen played out.
While new ways to carry out pool testing for SARS-CoV-2 abound, questions remain about sensitivity issues and the regulation of such tests.
The launch of the company's Prism system earlier this month should support the development of an accompanying menu of tests to serve diverse users.
The firm's Continuum system is fully automated and performs the entire digital PCR workflow in a single instrument.
In PLOS this week: computational strategy to study human population histories, BRAF mutational load in melanoma and disease progression, and more.
Genetron will provide clinical trial genomic testing and companion diagnostic development services for InnoCare's biomarker-driven oncology drug development.
The firm will apply the funds to development of a next generation of its digital PCR system as well as expansion in Asia.
On Monday Qiagen reiterated its preliminary 2019 earnings figures and addressed an investor's wrath, while Guardant Health highlighted its cancer testing plans.
The startup is exploring options with potential partners and plans to bring a urinary tract infection test through regulatory channels in the next two years.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.